JP2018505651A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505651A5
JP2018505651A5 JP2017526502A JP2017526502A JP2018505651A5 JP 2018505651 A5 JP2018505651 A5 JP 2018505651A5 JP 2017526502 A JP2017526502 A JP 2017526502A JP 2017526502 A JP2017526502 A JP 2017526502A JP 2018505651 A5 JP2018505651 A5 JP 2018505651A5
Authority
JP
Japan
Prior art keywords
antibody
disease
seq
hvr
bace1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526502A
Other languages
English (en)
Japanese (ja)
Other versions
JP6859259B2 (ja
JP2018505651A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061401 external-priority patent/WO2016081639A1/en
Publication of JP2018505651A publication Critical patent/JP2018505651A/ja
Publication of JP2018505651A5 publication Critical patent/JP2018505651A5/ja
Application granted granted Critical
Publication of JP6859259B2 publication Critical patent/JP6859259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526502A 2014-11-19 2015-11-18 BACElに対する抗体及び神経疾患免疫療法のためのその使用 Active JP6859259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081966P 2014-11-19 2014-11-19
US62/081,966 2014-11-19
PCT/US2015/061401 WO2016081639A1 (en) 2014-11-19 2015-11-18 Antibodies against bace1 and use thereof for neural disease immunotherapy

Publications (3)

Publication Number Publication Date
JP2018505651A JP2018505651A (ja) 2018-03-01
JP2018505651A5 true JP2018505651A5 (enExample) 2018-12-27
JP6859259B2 JP6859259B2 (ja) 2021-04-14

Family

ID=54782820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526502A Active JP6859259B2 (ja) 2014-11-19 2015-11-18 BACElに対する抗体及び神経疾患免疫療法のためのその使用

Country Status (5)

Country Link
US (2) US10882920B2 (enExample)
EP (2) EP3221364B1 (enExample)
JP (1) JP6859259B2 (enExample)
CN (1) CN107108745B (enExample)
WO (1) WO2016081639A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
CN108137681B (zh) 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
US11525002B2 (en) 2017-10-11 2022-12-13 Board Of Regents, The University Of Texas System Human PD-L1 antibodies and methods of use therefor
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
EP3768726B1 (en) 2018-03-23 2024-10-30 Board of Regents, The University of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
JP7514765B2 (ja) 2018-03-23 2024-07-11 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP7390301B2 (ja) 2018-03-23 2023-12-01 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ヒトpd-l2抗体およびその使用方法
CN108760661B (zh) * 2018-09-08 2023-06-09 重庆科技学院 一种石油废水重金属离子多通道检测芯片
EP3898667A2 (en) * 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Modified antibody fcs and methods of use
WO2020172528A1 (en) * 2019-02-22 2020-08-27 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
WO2021195326A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
DK4045533T5 (da) 2020-03-26 2024-07-29 Univ Vanderbilt Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2)
EP4142739A2 (en) 2020-04-27 2023-03-08 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5200339A (en) 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
HUT69771A (en) 1990-08-17 1995-09-28 Univ Boston Proteases causing abnormal degradation of amyloid beta-proteine precursors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6329163B1 (en) 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU1684097A (en) 1996-12-11 1998-07-03 Athena Neurosciences, Inc. Beta-secretase isolated from human 293 cells
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HK1044545A1 (zh) 1999-02-10 2002-10-25 Elan Pharmaceuticals, Inc. 贝他分泌酶组合物及其方法
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
GB9924957D0 (en) 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
TWI316960B (en) 2000-07-19 2009-11-11 Upjohn Co Substrates and assays for beta-secretase activity
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002025276A1 (en) 2000-09-22 2002-03-28 Wyeth Crystal structure of bace and uses thereof
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US20020157122A1 (en) 2000-10-27 2002-10-24 Wong Philip C. Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス,インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
CA2433446A1 (en) 2000-12-28 2002-07-11 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
ATE413884T1 (de) 2001-05-22 2008-11-15 Merck & Co Inc Beta-secretase-substrat und seine verwendung
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Gdp−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
US7166454B1 (en) 2002-05-24 2007-01-23 Schering Corporation Codon-optimized β-secretase and methods of refolding and processing
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003285892A1 (en) 2002-10-15 2004-05-04 Bristol-Myers Squibb Company Bace binding peptides and uses thereof
US7220833B2 (en) 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1473362A1 (en) 2003-05-02 2004-11-03 Elan Pharmaceuticals, Inc. Glycosylation variants of BACE
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20070185042A1 (en) 2003-08-08 2007-08-09 The Brigham And Women's Hospital, Inc. President And Fellows Of Harvard College Sirna based methods for treating alzheimer's disease
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
US20070149763A1 (en) 2003-10-15 2007-06-28 Bristol-Myers Squibb Company Beta secretase exosite binding peptides and methods for identifying beta secretase modulators
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP1680505A1 (en) 2003-11-06 2006-07-19 Exonhit Therapeutics S.A. Bace455, an alternative splice variant of the human beta-secretase
US7413737B2 (en) 2003-11-14 2008-08-19 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
ATE549404T1 (de) 2004-10-01 2012-03-15 Takeda Pharmaceutical Verfahren zum screening eines transmembranenzymhemmstoffs
KR101252306B1 (ko) 2004-10-04 2013-04-08 제넨테크, 인크. 간세포 성장 인자 활성화제의 조정제
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006279896A1 (en) 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating Alzheimer's disease
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
SI1973950T1 (sl) 2006-01-05 2015-01-30 Genentech, Inc. Anti-EphB4 protitelesa in postopki njihove uporabe
KR101459160B1 (ko) 2006-01-20 2014-11-19 제넨테크, 인크. 항-ephrinb2 항체 및 그의 사용 방법
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
CL2007001536A1 (es) 2006-05-30 2008-01-25 Genentech Inc Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US20100047232A1 (en) 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
KR20090114443A (ko) 2007-02-09 2009-11-03 제넨테크, 인크. 항-Robo4 항체 및 그의 용도
WO2008129023A2 (en) 2007-04-19 2008-10-30 Vib Vzw Oligonucleotide compositions for the treatment of alzheimer's disease
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ, エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
ES2447844T3 (es) 2008-04-03 2014-03-13 Vib Vzw Anticuerpos de dominio individual capaces de modular la actividad BACE1
EP2303926A1 (en) 2008-06-20 2011-04-06 Oklahoma Medical Research Foundation Immunogenic memapsin 2 -secretase peptides and methods of use
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
US20100233156A1 (en) 2009-03-09 2010-09-16 Georgetown University Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
AU2010261853B8 (en) 2009-06-15 2015-02-26 Katholieke Universiteit Leuven, K.U. Leuven R&D BACE1 inhibitory antibodies
KR102810907B1 (ko) 2010-07-16 2025-05-21 아디맵 엘엘씨 항체 라이브러리
AR083819A1 (es) * 2010-11-10 2013-03-27 Genentech Inc UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
KR20140031217A (ko) 2011-04-20 2014-03-12 로슈 글리카트 아게 혈액-뇌 차단벽의 pH 의존적 통과를 위한 방법 및 구축물
WO2013056054A2 (en) 2011-10-14 2013-04-18 Genentech, Inc Peptide inhibitors of bace1
AU2013266611B2 (en) 2012-05-21 2016-08-11 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
PL3587448T3 (pl) 2013-03-15 2021-11-29 Xencor, Inc. Białka heterodimeryczne
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法

Similar Documents

Publication Publication Date Title
JP2018505651A5 (enExample)
JP7109467B2 (ja) タウに特異的に結合する結合分子
JP2014502150A5 (enExample)
JP2018505652A5 (enExample)
IL266911B1 (en) Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss
JP2014502141A5 (enExample)
JP2016503065A5 (enExample)
JP2018519810A5 (enExample)
IL225568A (en) Phospho-specific antibodies for tau detection
JP2013500940A5 (enExample)
HRP20140333T1 (hr) A beta 1-42 specifiäśna monoklonalna antitijela sa terapeutskim svojstvima
JP2020513791A5 (enExample)
JP2019529336A5 (enExample)
JP2018531580A5 (enExample)
RU2014118456A (ru) Фосфоспецифичные антитела, распознающие тау
JP2021505142A (ja) タウに特異的に結合する結合分子
JP2022547513A (ja) アルツハイマー病及び軽度認知障害のバイオマーカー及び治療
JP2014502276A5 (enExample)
CN113906050A (zh) 抗EphA4抗体
CN116348487A (zh) 抗淀粉样β抗体
JPWO2021010712A5 (enExample)
US11274147B2 (en) Binding molecules that specifically bind to tau
JPWO2022132923A5 (enExample)
González-Artero et al. Passive immunotherapy for Parkinson’s disease in 2025: Status and perspective
NZ736553A (en) Use of semaphorin-4d binding molecules for treating neurodegenerative disorders